Drugs / Sovalteinib
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05958849 | Aug 2023 → Jul 2024 | — | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05911425 | Jul 2023 → Jun 2024 | bile duct cancer | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sovalteinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05911425 ↗ |
| Route | Oral | “orally” NCT05911425 ↗ |